Bioscience firm applies AI and data science to identify existing drugs Atozet and Cablivi as potentially effective therapies for blood clots and inflammation caused by COVID-19.
Two newly repositioned drugs with the potential to combat key symptoms of COVID-19 were announced on Aug. 25 by bioscience firm Biovista. The firm identified Cablivi and Atozet as particularly suited to target specific aspects of blood clotting and inflammation in the context of COVID-19.
This follows a mechanistic rationale Biovista released in March, suggesting Aprotinin and Irbesartan as potential COVID-19 treatments to reduce the effects of the cytokine storm, as well as helping reduce viral loads.
For more information, click here.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.